Combination of stem cell research and immunotherapy in gynecologic cancer

我们注意到CD 133是卵巢癌的干细胞标志物。本研究旨在评估卵巢YST细胞系中CD 133+细胞的成瘤能力，并检查CD 133+细胞的特性，如细胞生长和侵袭性。我们的数据表明，卵巢YST可能是由一种罕见的表达细胞表面标志物CD 133的癌症干细胞样细胞维持的。NOY 1-CD 133+细胞中CXCR 4水平显著高于CD 133-NOY 1细胞。NOY 1-CD 133+表达CD 44的水平略高于CD 133-。我们还检测了手术切除的卵巢癌组织中GPC 3的表达。我们尝试免疫疗法治疗卵巢癌。我们研究了癌胚抗原GPC 3的表达。结果表明，51.6%的卵巢透明细胞癌细胞表达GPC_3，而其他组织型的卵巢透明细胞癌细胞不表达GPC_3，GPC_3在细胞内和细胞膜上均有表达。此外，我们还发现，90%的卵巢透明细胞癌细胞表达HLA-Ⅰ类抗原。证明了GPC 3肽免疫治疗的有效性。我们开始了GPC 3衍生肽疫苗用于卵巢透明细胞腺癌患者的II期临床试验

We noticed CD133 as a stem cell marker in ovarian cancer. The present study was designed to evaluate the tumor-formation ability of CD133+ cells in ovarian YST cell lines and to examine characteristics of CD133+ cells such as cell growth, and invasiveness. Our data suggest that ovarian YST may be maintained by a rare fraction of cancer stem-like cells that express the cell surface marker CD133. CXCR4 levels were markedly higher in NOY1-CD133+ cells than CD133- NOY1 cells . NOY1-CD133+ expressed slightly higher levels of CD44 expression when compared with their CD133- counterparts.We also examined GPC3 expression in surgically resected ovarian carcinoma tissues. We tried immunotherapy in ovarian cancer. We investigated the expression ofonco-fetal antigen, GPC3. Our results showed that GPC3 was expressed in tumor cells from 51.6% of ovarian clear cell carcinoma although other histotypes were not stained, GPC3expression was observed in intracellular lesions as well as in the cell membrane, Furthermore, we showed that HLA-classI was expressed in tumor cells from 90% of ovarian clear cell carcinoma. We showed the validity of GPC3 peputide immunotherapy. We started a phase II clinical trial of the GPC3 derived peptide vaccine for ovarian clear cell adenocarcinoma patients